. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr. 2005;5:3. PubMed.


Please login to recommend the paper.


Comments on this Paper

No Available Comments

Make a Comment

To make a comment you must login or register.